8-K/A: Glucotrack Completes Merger, Adjusts Financials Post-Reverse Split

Glucotrack, Inc. files an amendment to its 8-K to update pro forma financials reflecting its merger with Lokahi Therapeutics and a 1-for-15 reverse stock split.

Summary

• This filing is an amendment to a previous 8-K report, specifically updating the unaudited pro forma financial statements.
• The updates reflect the merger between Glucotrack, Inc. and Lokahi Therapeutics Inc., which became effective on July 14, 2026.
• The pro forma financials also incorporate the impact of a 1-for-15 reverse stock split of Glucotrack's common stock, effective August 28, 2026.
• The combined entity reported a net loss of $19,699,822 for the six months ended June 30, 2026, and $28,135,308 for the year ended December 31, 2025.
• As of June 30, 2026, the combined entity had total assets of $53,501,018 and total liabilities of $25,302,892, resulting in total stockholders' equity of $28,198,127.
• Significant financing activities include bridge notes and warrants, with substantial day-one losses recognized on these instruments.
• The merger consideration involved shares of Glucotrack common stock and Series A convertible preferred stock, valuing the transaction at $33,327,384.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant ongoing losses, substantial debt, and the dilutive nature of recent financing activities, despite the strategic merger.

Positives

• The merger with Lokahi Therapeutics Inc. is completed, potentially creating a combined entity with enhanced capabilities.
• Pro forma balance sheet as of June 30, 2026, shows total assets of $53,501,018.
• The company has secured $2,000,000 in proceeds from an Interim PIPE financing.

Negatives

• Significant net losses reported: $19,699,822 for the six months ended June 30, 2026, and $28,135,308 for the year ended December 31, 2025.
• Substantial interest expense and losses on issuance of convertible notes are present.
• The company has recognized significant day-one losses on bridge financing, totaling $2,716,171 and $2,162,728 for two separate tranches.
• The fair value of convertible notes and warrants issued as part of bridge financing adds significant liabilities.
• The pro forma weighted average common shares outstanding for the six months ended June 30, 2026, is 299,517, and for the year ended December 31, 2025, is 118,729, reflecting the impact of the merger and reverse stock split.
• The company has an accumulated deficit of $165,374,258 as of June 30, 2026.

Risks

• The company has incurred substantial operating losses and may not achieve profitability.
• The significant debt and convertible notes could lead to future dilution or financial distress.
• The fair value accounting for derivative liabilities and warrants introduces volatility.
• The company has a history of financing through bridge notes with significant associated costs and losses.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the pro forma financial information presented. The pro forma statements are not intended to project future financial position or operating results.

Management Comments

• The unaudited pro forma condensed combined financial information is presented for illustrative purposes only and is not necessarily indicative of what the combined company's financial position or results of operations would have been had the transaction been completed on the dates assumed.
• The unaudited pro forma condensed combined financial information is not intended to project the future financial position or operating results of the combined company following completion of the transaction.

Industry Context

StockSavvy.ai notes that the merger and subsequent financial adjustments are common in the biotechnology and medical device sectors, where consolidation and strategic financing are often employed to advance product development and market entry. The recognition of significant intangible assets and goodwill is typical in such acquisitions.

Related Party Transactions

• Notes payable related party of $500,100 are listed on the pro forma balance sheet as of June 30, 2026.

Stakeholder Impact

• Shareholders: The 1-for-15 reverse stock split significantly reduces the number of outstanding shares, potentially impacting per-share metrics and market perception. The substantial losses and ongoing financing activities suggest potential future dilution.
• Creditors: The company has significant liabilities, including convertible notes and bridge loans, which will need to be serviced.
• Investors: The pro forma financials indicate a high-risk profile due to significant losses and complex financing structures.

Next Steps

• The company will continue to integrate Lokahi Therapeutics Inc. following the merger.
• Further financing may be required to fund ongoing operations and development, given the substantial net losses.
• The company may utilize the ELOC Purchase Agreement for future capital raises.

Key Dates

Recommendation

The filing reveals substantial ongoing net losses, significant debt financing with unfavorable terms (evidenced by large day-one losses on bridge notes), and a dilutive reverse stock split. While the merger is a strategic move, the current financial performance and capital structure present considerable risks that outweigh potential upside in the near term.

Keywords

Merger, Pro Forma Financials, Reverse Stock Split, Lokahi Therapeutics, Convertible Notes, Bridge Financing, Intangible Assets, Goodwill